• 1
    Hofman A, Ott A, Breteler MMB et al. Atherosclerosis, apolipoprotein E, and the prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 1514.
  • 2
    The Neuropathological Group of the Medical Research Council Cognitive Function and Ageing Study (CFAS). Pathological correlates of late-onset dementia in a multi-centre, community-based population in England and Wales. Lancet 2001; 357: 16975.
  • 3
    Snowden DA, Greiner LH, Mortimer KP, Riley KP, Markesbery WR. Brain infarction and clinical expression of Alzheimer's disease: the Nun study. JAMA 1997; 277: 8137.
  • 4
    Nagy Z, Esiri MM, Jobst KA et al. The effects of additional pathology on the cognitive deficit in Alzheimer's disease. J Neuropathy Exp Neurol 1997; 56: 10570.
  • 5
    Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol 1998; 55: 144955.
  • 6
    Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 234: 7186.
  • 7
    Seshadri S, Beiser A, Selhub J et al. Plasma total homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 47683.
  • 8
    Budge M, Johnston C, Hogervast E et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci 2000; 903: 40710.
  • 9
    Vermeer SE, Van Dijk EJ, Koudstaal PJ et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan study. Ann Neurol 2002; 51: 2859.
  • 10
    Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002; 59: 78793.
  • 11
    Homocysteine Lowering Trialist's Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998; 316: 8948.
  • 12
    Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 24955.
  • 13
    Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 1997; 23: 13747.
  • 14
    Practico DM-Y, Lee V, Trojanowski JQ, Rokach J, FitzGerald GA. Increased F2-isoprostane in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998; 12: 177783.
  • 15
    Montine TJ, Beal MF, Cudkowicz MEO et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999; 52: 5625.
  • 16
    Engelhart MJ, Geerlings MI, Ruitenberg A, Hofman A, Witteman JCM, Breteler MMB. Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA 2002; 287: 32239.
  • 17
    In'T Veld BA, Ruitenberg AG, Hofman A et al. Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease. NEJM 2001; 345: 151521.
  • 18
    Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading cognitive state of patients for the clinician. J Psychiatr Res 1975; 313: 141920.
  • 19
    Prince M, MacDonald AM, Sham PC, Richards M, Quraishi S, Horn I. The development and validation of a telephone-administered cognitive test battery (TACT). Int J Meth Psych Res 1999; 8: 4957.
  • 20
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA, 1994.
  • 21
    Bucks RS, Ashworth D, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living scale. Age Ageing 1996; 25: 11320.
  • 22
    Nexo E, Engbaek F, Ueland PM et al. Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine. Clin Chem 2000; 46: 11506.
  • 23
    Nexo E, Gimsing P. Insolubilized pure human intrinsic factor used for quantitation of cobalamin in serum. Scand J Lab Invest 1981; 41: 4658.
  • 24
    Molloy AM, Scott JM. Microbiological assay for serum, plasma and red-cell folate using cryopreserved, microtiter plate method. Meth Enzymol 1997; 281: 4353.
  • 25
    Lawson JA, Brash AR, Doran J, FitzGerald GA. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography-negative ion-chemical ionization mass spectrometry. Anal Biochem 1985; 150: 46370.
  • 26
    Practico D, Lawson JA, Fitzgerald GA. Cyclooxgenase-dependent formation of the isoprostane 8-epi prostaglandin F2 alpha. J Biol Chem 1995; 270: 98008.
  • 27
    Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. NEJM 1991; 325: 113741.
  • 28
    Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Sys-Eur) trial. Lancet 1998; 352: 134751.
  • 29
    PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 103341.
  • 30
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 722.
  • 31
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study randomised trial of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 2333.